Recent news coverage includes broader market and technology trends relevant to healthcare and AI but does not provide company-specific updates.

• Big Tech is on pace to spend $735 billion on AI data centers in 2026, highlighting the growing importance of AI infrastructure relevant to Biotricity's AI-driven cardiac monitoring efforts [N1].
• Stocks finished mixed as bond yields fell and chipmakers slid, reflecting broader market volatility [N2].
• Nvidia guided to $91 billion in revenue, underscoring the significance of AI hardware providers [N3].
• TOYO and Opera released Q2 2026 earnings call transcripts, indicating ongoing corporate earnings activity in the tech sector [N4][N5].
• Dollar fell and gold rallied as US CPI trailed estimates, impacting macroeconomic conditions [N6].
• Oil climbed to a 1-month high amid US-Iran tensions, affecting energy markets [N7].
• Stocks were supported as bond yields slid on weak CPI report, influencing market sentiment [N8].

Biotricity's comprehensive cardiac monitoring platform, combining FDA-cleared devices and AI-driven software, addresses a large and growing market driven by cardiovascular disease prevalence. The insourcing business model empowers physicians and supports recurring revenue growth. Strategic partnerships with Amazon and Google enhance AI capabilities and scalability. Expansion into chronic care management and remote patient monitoring markets offers additional growth avenues. The company's ongoing product development and regulatory clearances support a broadening product portfolio and market reach.

Biotricity faces challenges including a net loss and low liquidity ratios as of June 2026, indicating financial constraints. The competitive landscape includes established COM providers and alternative cardiac monitoring technologies. Regulatory approvals for new products are required and may delay market entry. Market adoption depends on successful sales force expansion and physician acceptance. The company's reliance on reimbursement rates and healthcare payer models introduces revenue risks. Technological advancements by competitors and changes in healthcare policies could impact market position.

Biotricity's moat is built on its FDA-cleared, integrated cardiac monitoring technology combining hardware and software, including proprietary AI algorithms for predictive cardiac care. The company's insourcing business model reduces operating overhead and facilitates efficient market penetration by enabling physicians to directly use and bill for the technology. Its partnerships with Amazon and Google provide access to advanced AI and cloud infrastructure, enhancing its technological capabilities. Regulatory approvals and the complexity of developing comprehensive COM solutions create barriers to entry for competitors. The company's expanding device ecosystem and recurring revenue model contribute to customer retention and competitive positioning.

• Financial Risk: The company reported a net loss of $959,468 for the quarter ended June 30, 2026, with a low current ratio of 0.15 and cash ratio of 0.01, indicating liquidity challenges.
• Regulatory Risk: Further FDA clearances are required for new products and software enhancements, which may delay commercialization and increase costs.
• Market Adoption Risk: Growth depends on expanding the sales force, market penetration, and physician acceptance of the insourcing business model and technology.
• Competitive Risk: The cardiac monitoring market has established competitors with alternative technologies; Biotricity must maintain technological and clinical advantages.
• Reimbursement Risk: Revenue relies on reimbursement rates from Medicare, Medicaid, and private insurers, which may vary and affect profitability.

• Biotricity Inc. is a medical technology company focused on biometric data monitoring solutions, targeting medical, healthcare, and consumer markets with diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.
• The company develops remote cardiac monitoring devices and software, including the Bioflux COM technology cleared by the FDA and commercially released in April 2019.
• Biotricity's product portfolio includes Bioflux, Bioheart (a direct-to-consumer heart monitor launched in 2021), Biocore (a three-lead ECG and arrhythmia monitoring device cleared by FDA in 2022), and Biocore Pro (cellular version launched in late 2024).
• The company uses an insourcing business model empowering physicians with technology and charges technology service fees, aiming to reduce operating overhead and improve market penetration.
• Biotricity focuses on utilization-based recurring technology fee revenue, growing sales force and market penetration to increase device placements with repeat clinical users.
• The company is expanding telemedicine capabilities including real-time streaming, remote patient monitoring, chronic care management, and implantable device management to create a unified cardiac platform.
• Biotricity is developing advanced ECG algorithms and next-generation Biocore Pro 2.0 device, with plans for further FDA clearances.
• The company has partnerships with Amazon and Google, leveraging AI technology, TensorFlow, AWS infrastructure, and big data to develop predictive cardiac monitoring tools.
• The cardiac AI model aims to improve disease profiling, patient management, and healthcare efficiency by supporting more patients and reducing human intervention.
• The company has expanded sales efforts to 35 US states and plans further expansion to compete broadly in the US market.
• The total addressable market includes hospitals, clinics, physicians' offices, and Independent Diagnostic Testing Facilities (IDTFs).
• Cardiac disease is the number one chronic care disease in the US and globally, driving demand for cardiac monitoring solutions.
• The US ECG market is segmented into event monitoring systems (including COM), stress ECG systems, and resting ECG systems, with COM preferred by physicians for continuous monitoring and faster diagnosis.
• Biotricity's Biocore solution offers a complete, turn-key, one-piece device with three ECG channels, designed for better data quality and patient compliance compared to competitors.
• The company is focused on chronic care and remote patient monitoring markets, which are growing due to aging populations and lifestyle-related illnesses.
• Financial snapshot as of 2026-06-30 shows cash and equivalents of $466,503, current assets of $5,596,042, current liabilities of $37,342,570, resulting in a current ratio of 0.15 and cash ratio of 0.01.
• Net income for the quarter ending 2026-06-30 was a loss of $959,468, with basic and diluted EPS of -$0.046 per share.
• Revenue data is limited, with a reported revenue of $398,200 for the fiscal year ended 2019-03-31.
• The company filed its latest 10-Q on 2026-08-19 and 10-K on 2026-07-14, providing detailed disclosures on business, market, products, and financials.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.